1 Frequent suboptimal thermocycler ramp rate usage negatively impacts MTBDRsl

2 performance for second-line drug resistant tuberculosis diagnosis

Brigitta Derendinger¹, Margaretha de Vos^{1,*}, Samantha Pillay¹, Rouxjeane Venter¹, John
Metcalfe², Yonas Ghebrekristos^{1,3}, Stephanie Minnies¹, Tania Dolby⁴, Natalie Beylis⁴, Robin
Warren¹, Grant Theron^{1†}

6 Affiliations:

- ¹DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, SA-MRC Centre for
- 8 Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of
- 9 Medicine and Health Sciences, Stellenbosch University, South Africa
- 10 ²Division of Pulmonary and Critical Care Medicine, Zuckerberg San Francisco General
- 11 Hospital, University of California San Francisco, USA
- ¹² ³National Health Laboratory Service, Groote Schuur Hospital, Cape Town, South Africa
- ¹³ ⁴National Health Laboratory Services, Green Point, Cape Town, South Africa
- ^{*}Current affiliation: Foundation for Innovative New Diagnostics, Geneva, Switzerland
- 15 [†]**Corresponding author**: Professor Grant Theron: <u>gtheron@sun.ac.za</u>
- 16 Short title: Suboptimal PCR ramp rate impacts MTBDRsl

17 Funding

- 18 This work is supported by the EDCTP2 program supported by the European Union (grant
- 19 SF1401, OPTIMAL DIAGNOSIS), The Center for Innovation in Point-of-Care Technologies

- 20 for HIV/AIDS at Northwestern University (National Institute of Biomedical Imaging and
- 21 Bioengineering of the National Institutes of Health, Award Number U54EB027049), and the
- 22 National Institute of Allergy and Infectious Diseases.
- 23 Research reported in this publication was also supported by the South African Medical
- 24 Research Council. The content is the solely the responsibility of the authors and does not
- 25 necessarily represent the official views of the South African Medical Research Council.
- 26 Hain Lifesciences donated the MTBDRsl kits used for the dilution series. They did not have
- any role in study design or result interpretation.

28 Abstract

Strengthening the detection of second-line drug-resistance is a key tuberculosis (TB) control priority. The performance of MTBDR*plus*, a multidrug-resistant (MDR)-TB assay is reduced when suboptimal ramp rates are used. We investigated ramp rate's effect on MTBDR*sl*; the most widely-used molecular second-line drug-resistant TB assay.

We tested 52 smear-negative Xpert MTB/RIF Ultra-positive sputa and a *Mycobacterium tuberculosis* (*Mtb*) dilution series at manufacturer-recommended (2.2°C/s) or most common suboptimal ramp rate (4.0°C/s; identified via an earlier survey). *Mtb*-complex DNA (TUBband)-positivity, indeterminate rates, fluoroquinolone- and second-line injectable-resistance accuracy, banding differences and, separately, inter-reader variability were assessed.

38 39% of re-surveyed laboratories (5/13) did not use the manufacturer-recommended 39 MTBDRsl ramp rate. On sputum, this ramp rate improved indeterminates vs. 4.0°C/s (0/52 40 vs. 7/51; p=0.006), false drug-resistance calls (0/104 vs. 6/102; p=0.013), and incorrect 41 banding calls (0/1300 vs. 55/1275; p<0.001). Valid results (neither TUB-negative, 42 indeterminate, nor any false drug-resistance calls) (52/52 vs. 41/51; p=0.001) on sputa hence 43 improved by +21% (95% CI: 8-34%) with optimal ramp rate usage. Suboptimal ramp rate 44 increased banding call inter-reader variability [52/1300 (4%) vs. 34/1300 (3%); p=0.030] on 45 sputa but not dilution series; highlighting the importance of using clinical specimens for 46 assay performance evaluations.

Suboptimal ramp rate contributes to poor MTBDR*sl* performance. Ramp rate correction will
improve second-line drug-resistant TB diagnoses. Laboratories must ensure the optimal
manufacturer-recommended ramp rate is used.

50 Introduction

In 2019, ~10 million people fell ill with tuberculosis (TB) and ~1.3 million people died¹. Drug resistant (DR)-TB is a global health problem. ~465 000 people having multidrug resistant (MDR)-TB, $\geq 6\%$ of which have additional resistance to (FQs) and second line injectables (SLIDs)¹. Worldwide only 52% of MDR-TB patients were tested for resistance to both these drug classes and only 58% of those who start treatment successfully complete it¹. Phenotypic culture-based drug susceptibility testing is slow and costly, and patients can wait six months before placed on effective treatment, if at all².

GenoType MTBDR*sl* (MTBDR*sl*; Hain Lifescience, Germany)³ is one of two commerciallyavailable rapid molecular World Health Organization (WHO)-endorsed assays for the detection of *Mycobacterium tuberculosis* (*Mtb*) complex and resistance to FQs and SLIDs⁴.
Per the WHO, MTBDR*sl* should be done directly on sputum irrespective of smear microscopy status to reduce the delay associated with culture for indirect testing⁴.

However, performance data for direct use on sputum are heterogenous. In a systematic
review and meta-analysis, smear-negative sensitivity estimates were imprecise: 80% [95%
confidence interval (CI) 28-99%], 80% (28-99%) and 50% (1-99%) for FQs, SLIDs and
XDR-TB, respectively⁵. This affected the certainty of evidence of the WHO recommendation
and undermined MTBDR*sl*'s uptake.

68 MTBDR*sl* requires thermocycling for DNA amplification. The manufacturer recommends a 69 ramp rate of $\leq 2.2^{\circ}$ C/s, which is the speed of temperature change between PCR cycles. We 70 previously showed Genotype MTBDR*plus* (MTBDR*plus*; Hain Lifescience, Germany) 71 performance, which is an assay for first-line resistance, is reduced when suboptimal 72 thermocycler ramp rates are used, most so on smear-negative specimens⁶. These findings are

incorporated into laboratory external quality assessment programmes and WHO TB
laboratory training material⁷.

75 If MTBDRsl is also vulnerable to this phenomenon, this would result in some of the 76 thousands of people who receive this assay each day having drug resistance diagnoses 77 missed; thereby resulting in resistance to the drugs critical to protect new regimens (e.g., FQ 78 to limit bedaquiline resistance acquisition in the oral second-line regimen) remaining delayed 79 or undiagnosed^{8,9}. More broadly, this issue of ramp rate is increasingly pertinent as 80 manufacturers are designing instruments with faster thermocycling (and hence faster ramp 81 rates) to decrease time-to-result. Furthermore, many thermocyclers, especially those at entry-82 level, do not have a customisable ramp rate.

We hypothesised that the heterogenous and suboptimal sensitivities reported for MTBDR*sl* on smear-negative specimens were partly attributable to suboptimal ramp rate and sought to generate empirical evidence of this. We assessed whether laboratories that reported use of suboptimal ramp rates during our MTBDR*plus* evaluation⁶ had switched to the manufacturer-recommended ramp rate, and what the observed effect had been.

88 Methods

89 Ethics statement

90 This study was approved by the Health Research Ethics Committee of Stellenbosch 91 University (N16/04/045) and Western Cape Research Ethics Committee 92 (WC_2016RP18_637). All methods were in accordance with relevant guidelines and 93 regulations. Permission was granted to access anonymised residual specimens collected as 94 part of routine diagnostic practices and thus patient informed consent was waived.

95 Experimental design

96 Ramp rate assessment was done in both an *in vitro* dilution series and clinical sputa (Figure 97 1). DNA extracted from dilution series and clinical specimens were split and compared 98 head-to-head at the manufacturer-recommended ramp rate of 2.2°C/s or the most common 99 suboptimal ramp rate of 4.0°C/s identified previously in a survey⁶. MTBDR*sl* was done on all 100 amplified DNA per manufacturer's instructions for use³. For sputa, programmatic MTBDR*sl* 101 results (done at the recommended ramp rate) were compared. All equipment is annually 102 calibrated and serviced.

103 MTBDRsl calls and result definitions

104 *CC band:* This must be present for a strip to be valid as it indicates hybridisation occurred.

105 *AC band:* Present when the assay is done correctly. Per the manual¹⁰, there are rare cases 106 where the AC band disappears due to competition during the amplification reaction. In this 107 scenario, an absent AC band in combination with TUB and locus control bands is still a valid 108 result.

- 109 Locus control bands (gyrA, gyrB, rrs, eis): Need to be present for a call from that locus to not
- 110 be indeterminate.
- 111 *Positive for Mtb-complex DNA:* TUB-band present.
- 112 *Strip banding call:* For a band to be classified as present, it must be equal or darker than the
- amplification control (AC) band. Overall, there are 27 possible strip bands on MTBDRsl.
- 114 When only the CC- and AC- bands are present, this represents a valid TUB-negative result.
- 115 Diagnostic call: Band presence or absence in a region determines whether the result is
- 116 classified as susceptible or resistance to a drug class (two diagnostic calls possible for
- 117 MTBDR*sl*: FQs or SLIDs).
- 118 (In)determinate for a gene region and/or drug class: For a specific gene region and/or drug
- class to be determinate, locus control band(s) must be present. We called a strip indeterminatefor a drug class if at least one gene locus control was absent.
- *Valid result*: TUB-band positive strip determinate for all gene locus controls and thus has
 diagnostic calls for both drug classes (e.g., TUB-band positive, FQ-resistant, SLIDssusceptible).

124 Impact of thermocycler ramp rate on MTBDRsl performance on a dilution series

A phenotypically- and genotypically-confirmed clinical XDR strain (known *gyrA*, *gyrB*, *rrs* and *eis* variants) and a drug-susceptible (DS) strain (H37Rv, ATCC 25618) were grown to mid-exponential phase (approximately 10⁸CFU/ml) in Middlebrook 7H9 media (Becton Dickinson, United States) supplemented with Middlebrook Oleic Albumin Dextrose Catalase (Becton Dickinson, United States). Serial dilutions in phosphate buffer supplemented with 0.025% Tween 80 (Merck, South Africa) were inoculated onto Middlebrook 7H10 solid

131 media (Becton Dickinson, United States) and incubated for 21 days at 37°C for colony forming unit (CFU) calculations. This was done in biological triplicate. 1ml of the 10^4 , 10^3 132 133 and 10²CFU/ml suspensions were GenoLysed (Hain LifeScience, Germany) and MTBDRs1 done per the manufacturer's instructions³. The two lower dilutions approximate to 134 smear-negative disease (<10 000CFU/ml)¹¹; expected to be most affected by suboptimal 135 136 ramp rate. DNA was amplified with the CFX96 thermocycler (Bio Rad Laboratories, South 137 Africa) at ramp rates of 2.2°C/s and 4.0°C/s. Two experienced readers recorded bands in a 138 blinded manner. Accuracy analyses for TUB-band positivity, indeterminate rates, incorrect 139 banding calls, and incorrect diagnostic calls were done.

140 Impact of thermocycler ramp rate on MTBDRsl on clinical specimens

Genolysed samples (n=52) remaining after programmatic LPA testing were collected from a TB laboratory in Cape Town, South Africa. These samples were, per the national algorithm, derived from the paired sputum specimen of a presumptive pulmonary TB patient that received Ultra (on a separate sputum), MGIT 960 culture and Auramine O microscopy (on the same sputum later GenoLysed). All sputa were smear-negative and Ultra-rifampicin resistant. We did not include smear-positives as we previously showed ramp rate to not affect MTBDR*plus* on smear-positives⁶. Residual GenoLysed samples were stored at -20°C.

Samples were categorised using programmatic LPA results as: 17 MDR-TB, 24 pre-XDR and 149 11 XDR-TB. For the experiment, DNA was amplified using a CFX96 thermocycler (Bio-150 Rad, United States) at 2.2°C/s (manufacturer-recommended) and 4.0°C/s. MTBDR*sl* was 151 done per the manufacturer's instructions³, and two experienced readers recorded bands in a 152 blinded fashion. Accuracy analyses for TUB-band positivity, indeterminate rates, incorrect 153 banding calls, and incorrect diagnostic calls were done.

154 Calculation of laboratory savings from an improvement in MTBDRsl performance om 155 smear-negatives stemming from ramp rate

We calculated how much the routine laboratory, from which we received GenoLysed remnants, would save if we applied the proportional increase we found in valid results when the optimal vs. the suboptimal ramp rate was used. This cost savings calculation was based on the average number of MTBDR*sl* tests done indirectly on cultured isolates per month (which would now be reduced due to direct testing on smear-negatives having improved performance) and the cost of each test (including consumables, labour, and overheads; the sum is pre-calculated supplied by the laboratory provider).

163 Inter-reader agreement

164 Three experienced readers read all strips from the dilution series and clinical specimens at 165 either ramp rate independently and in fashion blinded to each other's calls and any other 166 information regarding the specimens or strains used. Banding calls were assessed between 167 readers, as well as resultant differences in final diagnostic calls. Excluding the CC- and AC-168 bands, and including the TUB-band, gene locus control-bands and gene-specific wildtype-169 and mutant-bands, there are 25 possible bands per MTBDRsl strip. There are hence 450 170 possible bands total for the 18 samples in the dilution series and 1300 possible bands for the 171 52 clinical isolates. Each strip results in two diagnostic calls and there are hence 36 possible 172 diagnostic calls in total for 18 samples in the dilution series and 104 possible diagnostic calls 173 in total for the 52 clinical isolates.

174 Follow-up survey of TB diagnostic and research laboratories

We re-surveyed prior respondents (n=29) to our initial MTBDR*plus*-focussed survey⁶ to gather information on the current MTBDR*sl* conditions. We also surveyed for the first-time

- 177 other laboratories newly-known to us to do MTBDR*sl* on smear-negative specimens (n=11).
- 178 Initial non-responders were re-contacted at least twice. Survey questions included whether
- 179 ramp rate changed and impact on non-valid results (survey in Supplementary Material).
- 180 Permission to use data in an anonymised manner was obtained.

181 Statistical analyses

- 182 Analyses was done using Stata version 15 (StataCorp) and GraphPad Prism version 8.0.1
- 183 (GraphPad Software) using 2-sided tests with α =0.05. McNemar's test was used to calculate
- 184 differences for paired data (i.e., the same DNA tested at both ramp rates). The two-sample
- 185 proportion test was used for comparisons between proportions.

186 Data availability

187 Available from the corresponding author.

188 **Results**

189 MTBDRsl on the dilution series at different ramp rates

Overall, irrespective of ramp rate, MTBDR*sl* did not classify the XDR-TB strain correctly at 10² CFU/ml across all replicates. There were overall no differences between ramp rates of 2.2°C/s and 4.0°C/s for TUB-band detection [16/18 (89%) vs. 17/18 (94%) p=0.547], indeterminate results [2/16 (13%) vs. 3/17 (18%); p=0.680], incorrect banding calls [22/400 (6%) vs. 33/425 (8%); p=0.193)], or incorrect drug resistance calls [2/32 (6%) vs. 2/34 (6%); p=0.950] (**Table 1**). Therefore, valid results did not differ significantly [14/16 (88%) vs. 14/17 (82%); p=0.680].

197 MTBDRsl on clinical sputa at different ramp rates

198 No TUB-band detection differences were seen at 2.2°C/s vs. 4.0 °C/s [52/52 (100%) vs. 199 51/52 (98%), p=0.315; one MDR-TB patient was TUB-negative only at 4.0°C/s], however, 200 indeterminate rates improved at $2.2^{\circ}C/s$ [0/52 (0%) vs. 7/51 (14%); p=0.006] as did the 201 proportion of bands that appeared incorrectly [0/1300 (0%) vs. 55/1275 (4%); p<0.001)] and 202 drug-resistance calls [0/104 (0%) vs. 6/102 (6%); p=0.013] (Table 2). The proportion of 203 patients with a valid result was hence 52/52 (100%) vs. 41/51 (80%). In other words, the 204 patients who successfully received testing for FQs and SLIDs thus improved +21% (95% CI 205 8-34%, p<0.001).

Programmatic Ultra semi-quantitative data was available for 41/52 (79%) of sputa. When load in sputa that gave a valid result at 2.2°C/s was compared to samples that gave a valid result at 4.0°C/s, there were no significant differences [median (IQR) C_{Tmin} 18.7 (17.7-19.9) vs. 18.8 (18.0-19.9); p=0.899]. We had expected 2.2°C/s to result in an improved limit of

210 detection in MTBDR*sl* (better ability to detect higher C_{Tmin} sptua), however, we were not able 211 to detect differences.

212 Laboratory savings

213 If we apply the improvement in FQ and SLID testing due to optimal ramp rate usage, there 214 would be a 21% decrease in the number of tests required to be done indirectly (which would 215 require culture and a second MTBDRsl). At our local reference laboratory, ~320 MTBDRsls 216 initially attempted on smear-negative sputum are done per month are subsequently repeated 217 on culture isolates. Hence, in a scenario where this laboratory was using an incorrect ramp 218 rate and changed to the correct rate, they would do ~67 fewer indirect MTBDRsl tests per 219 month would need to be repeated. At a total per test cost of USD 60 (6% per annum inflation)¹² this translates to a saving of \$48 240 per year (only factoring in pure laboratory 220 221 costs).

222 Inter-reader agreement

In the dilution series, diagnostic calls did not differ between the three readers at either ramp rate – all readers incorrectly classified the XDR-TB strain (as either TUB-band negative or indeterminate) at all 10^{2} CFU/ml replicates and the DS-TB strain (as indeterminate) at one of the three replicates at 10^{2} CFU/ml (**Table 3**). The proportion of disagreement between readers (banding calls) did not differ at suboptimal vs. optimal ramp rates [for the DS (1/225 vs. 0/225; p=0.317) or XDR strain (3/225 vs. 1/225; p=0.313)].

In clinical sputa, however, although the disagreement in diagnostic calls did not differ between readers at the optimal vs. suboptimal ramp rate [5/104 (5%) vs. 8/104 (8%); p=0.390] banding calls, however, did [34/1300 (3%) vs. 52/1300 (4%); p=0.030].

232 Additional survey

233 Twenty-nine follow-up surveys were sent to the original respondents and 11 to new 234 laboratories. 13 total responses were received (45%), including four from new respondents 235 (Figure 2). 2/13 (15%) of respondents already had their ramp rate at 2.2°C/s (per their 236 response to our first survey) and 6/13 (46%) had subsequently changed their ramp rate to 2.2°C/s after we communicated our previous findings⁶. Concerningly, 5/13 (39%) had not 237 238 changed, for which varied reasons were offered (Table 4). Of the laboratories who changed 239 to 2.2° C/s, 4/6 (67%) reported that this resulted in an improvement in banding intensity and 240 fewer non-valid results for MTBDRplus and MTBDRsl.

241 **Discussion**

We evaluated for first-time thermocycler ramp rate's impact on the most widely used molecular test for second-line drug-resistant TB (MTBDR*sl*). We show: 1) in sputa valid results improved by 21% when using the optimal ramp rate, which results in significant laboratory cost savings and would decrease diagnostic delay, 2) banding call and drug susceptibility call reader disagreement worsened at the suboptimal ramp rate, and 3) several laboratory respondents had not corrected their LPA ramp rate but those that had reported fewer non-valid results from MTBDR*sl* on smear-negative specimens.

249 We had previously shown suboptimal thermocycler ramp rate negatively affects the 250 diagnostic accuracy of potentially thousands of MTBDRplus assays, especially on 251 smear-negative sputa⁶, and ramp rate monitoring was incorporated in laboratory quality 252 control and training documentation⁷. Now we show that a 21% increase of MTBDRsl 253 diagnoses (valid results) in smear-negative specimens is possible through ramp rate 254 correction. This is not a niche problem – we identified diagnostic laboratories who still do not 255 do MTBDRsl correctly. This correction, which we have now provided MTBDRsl-specific 256 empirical evidence could reduce DR-TB diagnostic care cascade gaps: a recent study found that only 65% of MDR-TB cases were evaluated for FQ resistance¹³. 257

258 Critically, ramp rate correction will reduce repeat MTBDR*sl* testing on isolates. Most 259 directly, this will translate into substantial laboratory cost savings in high burden countries, 260 especially when TB services are fragile due to the COVID-19 pandemic, not to mention the 261 myriad of other individual- and population-benefits that can stem from improved DST¹⁴, 262 including reduced time to treatment, transmission, and mortality.

263 Most laboratories in our follow-up survey had corrected ramp rate, however, a significant 264 amount, including those responsible for routine diagnostic testing on smear-negative 265 specimens, still used a suboptimal ramp rate. We re-iterate that 1) laboratories ensure that 266 they are using the optimal ramp rate, 2) thermocycler ramp rate monitoring be added to 267 laboratory external quality assurance programmes and accreditation processes for MTBDRsl, 268 and 3) that the manufacturer makes the recommended ramp rate more prominent in assay 269 documentation. It is worth evaluating further why incorrect ramp rates continued to be used. 270 This may be due to quality assurance lapses, a deliberate choice (e.g., to potentially speed up 271 turn-around-time) without an awareness of downsides, or a design limitation of available 272 thermocyclers.

We saw a more prominent performance difference between ramp rates in clinical sputa than in spiked solution. Bacilli in mucus sputa matrices behave differently to bacilli spiked in *in vitro* experiments and our findings illustrates potential downsides to investigating the effect of PCR parameters on molecular assays when *in vitro* or mock specimens are used.

277 Our evaluation has strengths and limitations. We did not assess a wider ramp rate range due 278 to limited sputa and cost but used the most frequently reported incorrect ramp rate. Our 279 survey results would have also been subjected to selection, response and reporting biases and 280 we suggest a formal survey is done by the manufacturer and/or the appropriate regulatory and 281 oversight agency (we did our survey independently). We did not evaluate savings stemming 282 from quicker diagnosis, treatment initiation, and long-term reductions in transmission and 283 mortality due to improved performance - there is already a saving in laboratory costs alone 284 with no downside.

In conclusion, we have shown that this incorrect and seemingly innocuous technical setting (ramp rate) has a real-world negative impact on patients' diagnoses for second-line drug

- 287 resistance using MTBDRsl. Smear-negative patients are especially vulnerable. All
- stakeholders must ensure that the optimal thermocycler ramp rate for MTBDR*sl* is used, and
- this requires investigation for other molecular diagnostics.

290 Acknowledgments

- 291 The authors thank the National Health Laboratory Services, Green Point, Cape Town, South
- 292 Africa, and Hain Lifescience, Germany.
- 293 The authors thank the laboratories that participated in the survey and provided data.

294 Author Contributions

- B.D., M.dV., G.T. and R.W. conceived the experiments. T.D. and S.P. provided specimens
- and data from the National Health Laboratory Service, Greenpoint. B.D. conducted the
- 297 experiments and analysed the data. S.P, Y.G., R.V. and S.M. assisted with analysis of results.
- 298 J.M. provided critical input. All authors reviewed the manuscript.

299 **Tables**

300 **Table 1.** MTBDRsl performance on a dilution series of drug susceptible- and XDR-TB strains (10⁴, 10³, 10² CFU/ml) at ramp rates of 2.2°C/s (manufacturer-recommended) or 301 302 4.0°C/s (3 replicates in triplicate for each ramp rate - 18 total MTBDRsl results). Accuracy 303 for TUB-band DNA and then further analysis of indeterminate rates, incorrect banding calls 304 and incorrect diagnostic calls were done. No significant differences were seen between ramp 305 rates using dilution series. P-values are for within-column comparisons between different 306 ramp rates. Data are n/N (%).

Down note	TUD hand	TUB-band positives				
Ramp rate (°C/s)	TUB-band positive	Indeterminate	Incorrect banding call	Incorrect diagnostic call	Valid result	
2.2	16/18*	2/16 [†]	22/400 [‡]	2/32	$14/16^{\dagger}$	
	(89)	(13)	(6)	(6)	(88)	
	17/18*	3/17 [†]	33/425 [§]	2/34 [¶]	$14/17^{\dagger}$	
4.0	(94)	(18)	(8)	(6)	(82)	
	p=0.547	p=0.680	p=0.193	p=0.950	p=0.680	

307 308 *2 strains \times 3 replicates \times 3 dilutions

[†]TUB-positive strips

[‡]16 TUB-band positive strips \times 25 bands per strip

 $^{\$}17$ TUB-band positive strips \times 25 bands per strip

^{$\|}16$ TUB-band positive strips \times 2 drug class diagnostic calls</sup>

309 310 311 312 313 314 315 316 317 [¶]17 TUB-band positive strips × 2 diagnostic calls

Definitions: TUB-band positive \Box positive for *Mycobacterium tuberculosis*-complex DNA; indeterminate \Box one or more

gene locus control is absent; incorrect banding call [] the presence or absence of a band deviating from the true banding call;

incorrect diagnostic call \Box the presence or absence of banding patterns resulting in deviation of the true susceptibility to a drug class; valid result 🗆 TUB-band positive, determinate for all gene locus controls, thus having diagnostic calls for both

drug classes.

318 **Table 2.** MTBDRsl performance on smear-negative sputa at ramp rates of 2.2°C/s 319 (manufacturer-recommended) or 4.0°C/s (52 isolates). Accuracy for Mycobacterium 320 tuberculosis-complex DNA (TUB-band), and then further analysis of indeterminate rates, 321 incorrect banding calls and incorrect diagnostic calls were done. The number of valid results 322 [52/52 (100%) vs. 41/51 (80%)] improved by 21% (95% CI: 8-34%; p<0.001). P-values are 323 for within-column comparisons between different ramp rates. Data are n/N (%).

Down voto	TUB-band positive	TUB-band positives				
Ramp rate (°C/s)		Indeterminate	Incorrect banding call	Incorrect diagnostic call	Valid result	
2.2	52/52*	0/52 [†]	0/1300‡	0/104	52/52 [†]	
	(100)	(0)	(0)	(0)	(100)	
	51/52*	7/51 [†]	55/1275 [§]	6/102¶	41/51 [†]	
4.0	(98)	(14)	(4)	(6)	(80)	
	p=0.315	p=0.006	p<0.001	p=0.013	p=0.001	

324 ^{*}Total number of clinical specimens

325 326 327 328 329 330 [†]TUB-positive strips

[‡]52 TUB-band positive strips \times 25 bands per strip

 $^{\$}51$ TUB-band positive strips \times 25 bands per strip

52 TUB-band positive strips $\times 2$ drug class diagnostic calls

[¶]51 TUB-band positive strips \times 2 drug class diagnostic calls

Definitions: TUB-band positive \Box positive for *Mycobacterium tuberculosis*-complex DNA; indeterminate \Box one or more

331 gene locus control is absent; incorrect banding call \square the presence or absence of a band deviating from the true banding call;

332 333 334 incorrect diagnostic call \Box the presence or absence of banding patterns resulting in deviation of the true susceptibility to a drug class; valid result 🗆 TUB-band positive, determinate for all gene locus controls, thus having diagnostic calls for both

drug classes

335 Table 3. Comparison of banding and drug susceptibility calls done on a dilution series of 336 drug susceptible- and XDR-TB strains and clinical specimens interpreted by three 337 experienced readers. Differences in banding calls or diagnostic calls did not differ between 338 the three readers at either ramp rate for the dilution series of cells, neither did the drug 339 susceptibility calls in the clinical specimens, however, significant difference between readers 340 for banding calls on the clinical sputa occurred. P-values are for within-column comparisons 341 between different ramp rates. Data are n/N (%).

	DS-TB strain		XDR-TB strain		Clinical specimens	
Ramp rate (°C/s)	Different banding call between readers	Different diagnostic call between readers	Different banding call between readers	Different diagnostic call between readers	Different banding call between readers	Different diagnostic call between readers
2.2	0/225 [*]	0/18 [†]	1/225 [*]	0/18 [†]	34/1300 [‡]	5/104 [§]
	(0)	(0)	(0.4)	(0)	(3)	(5)
4.0	1/225 [*]	1/18 [†]	3/225 [*]	0/18 [†]	52/1300 [‡]	8/104 [§]
	(0.4)	(6)	(1)	(0)	(4)	(8)
	p=0.317	p=0.311	p=0.313	p>0.999	p=0.030	p=0.390

342 *1 strain \times 3 replicates \times 3 dilutions \times 25 bands per strip

[†]1 strain \times 3 replicates \times 3 dilutions \times 2 diagnostic calls

343 344 345 [‡]52 clinical specimens \times 25 bands per strip

52 clinical specimens $\times 2$ drug class diagnostic calls

346 Definitions: DS-TB 🗆 drug susceptible-tuberculosis; XDR-TB 🗆 extensively drug resistant-tuberculosis; banding call 🗆 the

347 presence or absence of a band deviating from the true banding call; diagnostic call \Box the presence or absence of banding

348 patterns resulting in deviation of the true susceptibility to a drug class

Table 4. Laboratories that indicated their ramp rate had not yet changed to the manufacturer-recommended ramp rate of $\leq 2.2^{\circ}$ C/s since the last survey, the reason why, and total number of line probe assays done per month. These laboratories do either MTBDR*plus*, MTBDR*sl* or both on smear-negative specimens but data on the subtotals for each assay were

not collected.

Country	Reason given	Number of line probe assays done per month by this respondent laboratory
Kenya	Do not know	240
South Africa	Ramp rate change was not necessary as MTBDR <i>plus</i> assays are done on cultured isolates only and no MTBDR <i>sl</i> assays are done, as well as any changes to a standard operating procedure requires a validation process	40
Belarus	Ramp rate change in a standard operation procedure is not permitted without a prior approval process	155
Denmark	Ramp rate was not changed due to the run time of the original amplification protocol being faster	25
Spain	The thermocycler did not permit a ramp rate change	12

354

355 Figure legends

$0^3, 10^2$
(

- 357 CFU/ml)] experiment and (B) clinical experiment (sputa) to assess the impact of
- 358 thermocycler ramp rate on MTBDRsl. DNA extracted from the dilution series and clinical
- 359 specimens was split and MTBDRsl compared head-to-head at the manufacturer-recommend
- 360 ramp rate of 2.2°C or 4.0°C/s. TB \Box tuberculosis; DS-TB \Box drug susceptible tuberculosis;
- 361 XDR-TB \square extensively drug-resistant tuberculosis; CFU \square colony forming units; ml \square
- 362 millilitre

Figure 2. Follow-up survey results summarising thermocycler ramp rates for MTBDR*sl*. 2/13 (15%) of initially surveyed laboratories already had their ramp rate set to 2.2°C/s and 5/13 (39%) were still using a suboptimal ramp rate of \geq 2.2°C/s upon resurveying. 6/13 (46%) of laboratories had, since our first survey on MTBDR*plus*, changed MTBDR*sl* ramp rate to the recommended ramp rate. Of these, 4/6 (67%) reported an improvement in banding intensity and fewer invalid results.

369 **References**

370 1. World Health Organization. Global tuberculosis report 2020. 2020.

3712.Basu S, Friedland GH, Medlock J, et al. Averting epidemics of extensively drug-resistant372tuberculosis. 2009; 106(18): 7672-7.

373 3. Hain LifeScience. GenoType MTBDRsl VER 2.0 Instructions for Use. 2015.

World Health Organization. The use of molecular line probe assays for the detection of
 resistance to second-line anti-tuberculosis drugs: policy guidance. 2016.

3765.Theron G, Peter J, Richardson M, Warren R, Dheda K, Steingart KRJCDoSR. GenoType®377MTBDRsl assay for resistance to second-line anti-tuberculosis drugs. 2016; (9).

Berendinger B, de Vos M, Nathavitharana RR, et al. Widespread use of incorrect PCR ramp
 rate negatively impacts multidrug-resistant tuberculosis diagnosis (MTBDRplus). *Scientific reports* 2018; 8(1): 3206.

World Health Organization. Drug-resistant tuberculosis: how to interpret rapid molecular
 test results. 2020. <u>https://openwho.org/courses/multi-drug-resistant-tb</u>.

383 8. World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis
 384 treatment. 2019. <u>http://www.ncbi.nlm.nih.gov/books/NBK539517/</u> (accessed 02 April 2020.

385 9. Dowdy DW, Theron G, Tornheim JA, Warren R, Kendall EA. Of Testing and Treatment:
 386 Implications of Implementing New Regimens for Multidrug-Resistant Tuberculosis. *Clinical Infectious* 387 *Diseases* 2017: cix486.

38810.HainLifeScience.GenoTypeMTBDRplusVER2.0InstructionsforUse.2014.389https://www.ghdonline.org/uploads/MTBDRplusV20212304A-02-02.pdf.


390 11. Hobby GL, Holman AP, Iseman MD, Jones JM. Enumeration of tubercle bacilli in sputum of 391 patients with pulmonary tuberculosis. *Antimicrobial agents and chemotherapy* 1973; **4**(2): 94-104.


39212.Groessl EJ, Ganiats TG, Hillery N, et al. Cost analysis of rapid diagnostics for drug-resistant393tuberculosis. 2018; **18**(1): 1-10.

39413.De Vos E, Scott L, Voss De Lima Y, et al. Management of rifampicin-resistant TB: programme395indicators and care cascade analysis in South Africa. 2021; 25(2): 134-41.

39614.Dheda K, Gumbo T, Maartens G, et al. The Lancet Respiratory Medicine Commission: 2019397update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-398resistant and incurable tuberculosis. 2019; 7(9): 820-6.

399





(no change seen)

Changed ramp rate to 2.2°C/s after communication of our previous findings